BOGOTA, Feb 16, 2022 /PRNewswire/ — CannabCo Pharmaceutical Corp. Colombia S.A.S. (CannabCo Colombia), a Colombia-based cannabis cultivator and manufacturer of medical cannabis products, is pleased to announce the procurement of an enhanced integrated extraction platform to be deployed in their Colombian extraction facility.

The equipment to be installed in CannabCo Colombia’s facility, located 45 minutes outside Bogotá, will facilitate the processing of over 100,000 lbs of hemp and cannabis biomass monthly with expandability to over 500,000 lbs as needed.  While the sheer volume of the system makes it one of the most capable extraction processing centers in South America, the true value of the production line is the ability to inline process and “winterize” the extracted oil product with no human intervention.

Above: Factory acceptance testing of South America’s most advanced cannabis extraction equipment.

“One of the most tedious, time consuming, and ultimately costly tasks is that of winterization”, said CannabCo Colombia’s Chief Business Development Officer Phillip Chen.  “By utilizing a customized in-line process, we greatly increase productivity and decrease costs associated with the extraction process”.  Mr. Chen further mentions that the lack of human intervention also decreases the risk of contamination and increases overall product purity.

Winterizing involves the removal of fats, lipids, waxes, chlorophyll and other undesirables from bulk cannabis oil prior to distillation.  The most common winterization method is taking the oil and dissolving it in sub-zero ethanol at -20 to -80C.  This removes the undesirable compounds and leaves the processor with a semi-refined product.  The processor then filters and separates the ethanol from the valuable winterized oil which can now be used for various products such as vaporizers or edibles, or further processed to a highly concentrated and purified distillate.  This multi-step process is labour intensive, subjects the operator to harmful solvents and fumes, and can take between 24 to 72 hours to complete.  Overall it adds complexity and significant cost to the process of refining Cannabis.

“We simplify the entire extraction process whereby cannabis biomass goes in one end and refined winterized hemp or cannabis oil comes out the other” says Phillip.  “The goal of the company is to always have an eye for increased efficiency, product quality, and cost reduction and we have achieved all these factors with our system”.  The entire batch process takes hours instead of days and is highly efficient.

The CannabCo extraction line is being hailed as one of, if not the, most advanced extraction system in South America and will be used to process biomass supplied from the company’s three agricultural projects which boast over two million sq/ft of greenhouse production when completed.  In addition the company has extraction agreements for processing of third party biomass from independent farms in the region.

About CannabCo Pharmaceutical Corp. Colombia S.A.S.
CannabCo Colombia is a Colombia based full service cannabis company with cultivation projects in multiple regions across the country. The company’s primary extraction plant is located 30 minutes outside the capital city of Bogotá. The company will process both psychoactive and non-psychoactive cannabis and hemp flower for the production of THC and CBD oil for the medical cannabis market.  The company’s state of the art production facilities will have the capability of producing a wide range of end products to meet emerging market supply requirements for Colombia’s evolving cannabis industry, as well as global export. The facility is pursuing EU GMP status allowing access to the underserviced global pharmaceutical market. The company currently has multiple social projects as part of its ethical standards and is committed to the highest quality production of medical grade cannabis products in the industry. The company is vertically integrated controlling all aspects of cultivation, extraction, product manufacturing, and distribution of its medical products allowing it full control over the high quality of its end products. The company intends to be the largest producer and manufacturer of THC/CBD based products on a global scale utilizing Colombia as its operating base.

Forward Looking Statements
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by  statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Actual results and developments may differ materially from those contemplated by these statements. Although CannabCo Colombia believes that the expectations reflected in forward-looking statements in this press release are reasonable, there can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements in this press release.

Contact: Investor Relations

[email protected]
www.cannabco.co

SOURCE CannabCo Pharmaceutical Corp. Colombia S.A.S.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• First biotechnology company engaged in the production of Cannabis biomass and cannabinoids to publish an ESG report and commit to tangible, science-based targets
• BioFarming manufacturing process uses 99.99% less land than traditional outdoor agriculture, while generating no direct greenhouse gases “GHG” emissions, no hazardous waste, and producing 100% biodegradable wastewater
• Committed to further reducing its environmental footprint while scaling production
• Directly supports four United Nations Sustainable Development Goals

BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) today announces the publication of its inaugural Environmental, Social, and Governance (ESG) Report, detailing the Company’s performance and ongoing commitment to creating a sustainable future. BioHarvest is the first biotechnology company engaged in the production of Cannabis and cannabinoids to publish a comprehensive ESG report that commits to meaningful science-based targets over the next five years.

Sustainability has always been at the core of BioHarvest, with the Company’s BioFarming technology allowing it to produce active plant ingredients without having to grow the plant itself. This practice substantially reduces resource requirement in general, as well as greenhouse gas emissions – which would otherwise be generated – and prevents biodiversity loss. For example, the Company:

• Uses 99.99% less land than traditional agriculture
• Produces zero Scope 1 or direct GHG emissions in the BioFarming manufacturing process
• Uses no solvents or pesticides in the manufacturing process, resulting in wastewater that is 100% biodegradable and contains no chemicals
• Produces no hazardous waste in the BioFarming manufacturing process

The report details the policies, metrics, and programs that support each of the Company’s four key ESG pillars:

1. Product: Promoting pure well-being by providing fully traceable, science-based and innovative products with proven health benefits that improve the well-being of our customers.
2. Process: Demonstrating the minimal footprint of our production process while striving to reduce any adverse impact on water use, climate, and the environment.
3. People: Supporting our people by treating them with the utmost respect, the safest working conditions and allowing them to develop and thrive in the workplace; and
4. Governance: Setting the standard for end-to-end sustainability, ethical marketing, business ethics, and transparency in our industry.

The report is aligned with the United Nations Sustainable Development Goals and the reporting requirements of the Task Force on Climate-Related Financial Disclosures and the Sustainability Accounting Standards Board.

While the report primarily focuses on the production of VINIA® (see: https://bioharvest.com/wp-content/uploads/2021/07/BioHarvest-Sustainability-Report-14July-21.00.pdf ),  it provides important insights on how that production process can transform global Cannabis production. The Company recently announced a significant breakthrough ( See News Release dated July 7, 2021 ) in its production of Cannabis and is on track to reach commercialisation in H1 2022. The sustainability advantages which will accrue from the Cannabis vertical, will be benchmarked versus the industry and highlighted in the Company’s 2022 sustainability report.

” I could not be more excited to release our inaugural ESG report and share the incredible progress we have made over the past 10 years to help create a more sustainable future. Unlike other companies, sustainability is not something we feel compelled to support; to the contrary, it is at the core of our technology, which unlocks the cellular biological secrets of the plant kingdom, ” said Ilan Sobel , CEO of BioHarvest Sciences. ” As the company grows, we want to redouble our efforts to ensure that our transparency, governance, environmental and social record remains best-in-class for the nutraceutical and cannabis industries as well as future verticals we expand into with our BioFarming technology.”

Eitan Popper , Chairman of BioHarvest’s Board of Advisors, and co-founder and previous President of MedReleaf, added, “Based on my knowledge of the industry , BioHarvest is currently the only Company in the Cannabis sector, that is effectively pursuing a sustainability agenda through its core technology. ” Mr. Popper also highlighted the reduced energy related impact when it comes to Cannabis production: “A large portion of North America’s Cannabis production capacity is based on indoor cultivation, which is extremely energy intensive, and represents a major challenge as the industry continues to grow. BioHarvest’s process will require substantially less energy when compared to both indoor and greenhouse Cannabis production. Ultimately, this doesn’t only reduce the per gram CO2 footprint by a few orders of magnitude, it obviously also reduces the cost”.

To download a copy of the ESG report , please visit: https://bioharvest.com/wp-content/uploads/2021/07/BioHarvest-Sustainability-Report-14July-21.00.pdf

About BioHarvest Sciences Inc.

Based in Vancouver , BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to also become a leading supplier of Cannabis for both medicinal and legal recreational purposes. For more information visit: www.bioharvest.com .

BioHarvest Sciences Inc.
Ilan Sobel , Chief Executive Officer

Forward-Looking Statements

Information set forth in this news release includes might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance our production method will meet its potential of transforming Cannabis production or that we will be able to commercialize our first Cannabis products in the first half of 2022. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the Company is in the process of constructing a two-ton production facility the Company’s current licensing only permits scientific research. Projected sales of Cannabis will require the Company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.